ASP Isotopes, a pre-commercial stage advanced materials company, filed on Monday with the SEC to raise up to $30 million in an initial public offering.
ASP Isotopes is a pre-commercial stage advanced materials company initially focused on the production and commercialization of enriched Molybdenum-100 ("Mo-100"). The company believes that the Mo-100 it may develop has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry. ASP Isotopes has no products approved for commercial sale or existing customers and has generated no revenues to date.
The Boca Raton, FL-based company was founded in 2021 and plans to list on the Nasdaq under the symbol ASPI. Revere Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
